FDA clears first-of-its-kind Duchenne drug for broad use [Yahoo! Finance]
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: Yahoo! Finance
Duvyzat, a medicine developed by Italian pharmaceutical company Italfarmaco and to be sold in the U.S. by its subsidiary ITF Therapeutics. Duvyzat is the first non-steroidal treatment approved for use in all Duchenne patients who are at least six years of age, regardless of their disease's genetic underpinnings. The drug is a pill designed to slow inflammation and muscle loss. In testing, it was associated with statistically significant benefits, compared to a placebo, on measures of motor function. The drug's price hasn't been determined yet, according to an ITF spokesperson. Its labeling information requires healthcare providers to evaluate patients' platelet counts and triglycerides before prescribing Duvyzat, and to monitor levels of each afterwards. The most common side effects associated with treatment were diarrhea, stomach pain, nausea and vomiting. Dive Insight: The treatment landscape for Duchenne, a progressive and typically fatal neuromuscular disease, has changed
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings [Yahoo! Finance]Yahoo! Finance
- Bullish Sarepta Therapeutics Insiders Loaded Up On US$13.3m Of Stock [Yahoo! Finance]Yahoo! Finance
- Sarepta Therapeutics to Announce First Quarter 2024 Financial ResultsBusiness Wire
- GSK Gears Up for Q1 Earnings: Here's What to Expect [Yahoo! Finance]Yahoo! Finance
- IRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in Columbus [Yahoo! Finance]Yahoo! Finance
SRPT
Earnings
- 2/28/24 - Beat
SRPT
Sec Filings
- 4/24/24 - Form DEF
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- SRPT's page on the SEC website